XM does not provide services to residents of the United States of America.
R
R

Regeneron

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

What to Watch in the Week Ahead and on Monday, October 28

What to Watch in the Week Ahead and on Monday, October 28 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY Ford is expected to report higher third-quarter revenue and profit, aided by sales of its commercial vehicles.
A
A
B
C
C
C
C
D
G
I
J
M
P
P
R
S
K
K
E
R
U

U.S. Coca-Cola, Nextera Energy Partners, ServiceNow

U.S. RESEARCH ROUNDUP-Coca-Cola, Nextera Energy Partners, ServiceNow Oct 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Coca-Cola, Nextera Energy Partners, and ServiceNow on Thursday. HIGHLIGHTS * Avery Dennison Corp AVY.N : JP Morgan cuts to neutral from overweight * Coca-Cola Co KO.N : JP Morgan cuts target price to $75 from $78 * Nextera Energy Partners LP NEP.N : JP Morgan raises to neutral from underweight *
A
A
A
B
C
D
D
E
E
N
R
C
L
T
E
E
I
S
T
A
A
E
E
G
H
L
R

Regeneron loses bid to block Amgen's Eylea biosimilar launch in US

UPDATE 1-Regeneron loses bid to block Amgen's Eylea biosimilar launch in US Adds comments from Regeneron and Amgen in paragraphs 3-4, additional context in paragraphs 5-8 By Blake Brittain Oct 22 (Reuters) - Amgen AMGN.O will launch its biosimilar version of Regeneron's REGN.O blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.
A
R

Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case

Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case By Blake Brittain Oct 22 (Reuters) - Amgen AMGN.O will launch its biosimilar version of Regeneron's REGN.O blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to temporarily block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia.
A
R

Three-Year Results For Eylea Hd (Aflibercept) Injection 8 Mg Demonstrate Continued Durable Vision Gains And Anatomic Improvements With Extended Dosing Intervals In Patients With Diabetic Macular Edema

BRIEF-Three-Year Results For Eylea Hd (Aflibercept) Injection 8 Mg Demonstrate Continued Durable Vision Gains And Anatomic Improvements With Extended Dosing Intervals In Patients With Diabetic Macular Edema Oct 18 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : THREE-YEAR RESULTS FOR EYLEA HD® (AFLIBERCEPT) INJECTION 8 MG DEMONSTRATE CONTINUED
R

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.